Phantom Equity and SARs: How Non-Standard Equity Instruments Create Series B Valuation and Governance Confusion

Phantom equity, stock appreciation rights (SARs), and profits interests serve as highly flexible compensation tools, yet their tendency to live outside standard cap tables creates immense valuation and governance confusion during a Series B raise. Because these non-standard instruments are invisible to first-pass cap table reviews, institutional lead investors often treat their mid-diligence discovery as a severe disclosure failure rather than a minor technical oversight. These plans introduce significant financial complexities, including senior contingent cash claims on exit proceeds, waterfall modeling ambiguities, and escalating corporate balance sheet liabilities under FASB ASC 718. Furthermore, un-subordinated contractual vetoes or misaligned payout triggers can quietly compromise preferred stockholder protections. Rather than running the risk of a repriced round or a sudden investor withdrawal, founders must aggressively document every non-standard arrangement, stress-test contingent payout schedules, and contractually subordinate plan terms before opening their data room to institutional capital.

When a lead investor opens your data room and finds a phantom equity plan or SAR program that was not disclosed upfront, three questions surface immediately. What is the true fully diluted ownership? What contingent cash obligations does the company carry at exit? And do any contractual rights in these plans conflict with preferred stockholder protections or the financing itself? A Series B lead who cannot answer those questions from your materials does not wait for clarification. They reprice the round or walk.

This guide explains the mechanics of each instrument type, the specific valuation and governance problems they create at Series B, and what must be resolved before you approach a lead investor. For a broader view of the cap table issues that can derail a round before diligence even begins, see the complete guide to cap table problems that kill a Series B.

Key takeaways:

• Phantom equity and SARs do not appear on a standard cap table, which means they can stay invisible until a lead investor's legal team surfaces them mid-diligence.
• Undisclosed non-standard instruments are treated as a disclosure failure, not a technical issue. The credibility damage compounds the economic problem.
• Cash-settled SARs can function as liabilities under ASC 718 accounting guidance, which affects enterprise value calculations independently of equity dilution.
• Profits interests in LLC structures can create waterfall ambiguity that institutional investors cannot model without full plan documentation.
• The fix is not always conversion. Proper disclosure, subordination, and a clear contingent-obligation schedule are often sufficient, if done before the raise begins.

What Phantom Equity, SARs, Profits Interests, and Synthetic Equity Actually Are

These instruments share one structural feature: they create economic rights tied to company value without issuing actual stock. Founders use them for legitimate reasons, including compensating international employees who cannot hold U.S. equity, rewarding advisors quickly without a 409A, or granting upside before a formal option plan is in place.

The definitions matter because each instrument creates a different type of obligation and a different diligence problem.

Why Founders Issue These Instead of Standard Options

Standard options require a 409A valuation, a formal equity plan, board approval, and compliance with IRS Section 409A nonqualified deferred compensation rules. Non-standard instruments can be issued faster, work across jurisdictions, and avoid some of that administrative overhead.

The tradeoff is that the speed and flexibility that made these instruments attractive at the seed stage become liabilities at Series B, when institutional investors need a clean, fully documented ownership picture before they will commit capital. Founders who stacked SAFEs alongside phantom plans face compounding diligence problems, as covered in the guide on how stacked SAFEs detonate at your Series B.

Why These Instruments Create Valuation Problems at Series B

Institutional investors underwrite a Series B based on what they can model. Non-standard instruments introduce three specific valuation problems that disrupt that underwriting.

1. Contingent cash obligations reduce exit proceeds available to preferred stockholders.

A phantom equity plan payable at exit is essentially a senior claim on liquidity proceeds. If the plan covers 5% of the company's equity value and the exit is at $100M, that is $5M leaving the waterfall before preferred and common holders receive anything. Most phantom plans do not appear in the capitalization table, which means the investor's financial model is structurally wrong until the plan is disclosed.

2. Cash-settled SARs are treated as liabilities, not equity.

Under FASB ASC 718 guidance on share-based payment, cash-settled awards are classified as liabilities and remeasured at fair value each reporting period. That means the obligation grows as the company's value grows. An investor calculating enterprise value must account for this growing liability, or they will overpay for the equity.

3. Profits interests with undefined thresholds create waterfall ambiguity.

Profits interests issued in LLC structures participate in distributions above a threshold value set at grant. If the threshold, participation mechanics, or distribution priority are not clearly documented, investors cannot model the exit waterfall. Ambiguous waterfall mechanics are a deal-stopper at institutional diligence.

Illustrative Exit Scenario

The obligation scales with value. A lead investor who does not see this in the data room will find it in the legal review and adjust the offer accordingly. For founders who also carry convertible note or SAFE overhang from the seed stage, the compounding effect on Series B economics is significant, as detailed in the guide on how SAFE notes and convertible notes silently destroy your Series B cap table.

Why These Instruments Create Governance and Diligence Problems

The valuation issues are significant. The governance issues can be worse, because they go to control, not just economics.

Phantom plans and SAR agreements are contracts. Delaware courts enforce contracts. That means the rights in those documents are real legal obligations, regardless of whether they appear anywhere near the corporate charter or the cap table. Institutional investors reviewing NVCA model financing documents and preferred stock protections need to confirm that no side contract undercuts those protections.

Specific governance risks investors flag

• Consent or approval rights. Some phantom plans require company consent before amendment, termination, or transfer. If that consent right is not subordinated to preferred stockholder protections, it can create a veto point that complicates the financing.
• Payout mechanics that conflict with liquidation waterfalls. A phantom plan that pays out "upon any liquidity event" may be triggered by the financing itself if the round is structured as a partial liquidity event, depending on the plan's definition.
• Information rights. SAR agreements sometimes include information rights for participants. Those rights may not be consistent with the confidentiality obligations in the financing documents.
• Undisclosed side letters or amendments. Plans that were amended informally or supplemented by side letters create additional diligence exposure.

The investor's read: A mid-diligence discovery of an undisclosed phantom plan is not treated as an oversight. It signals that management either did not know what was on its own cap table or chose not to disclose it. Either interpretation damages the lead investor's confidence in the team, and that confidence is harder to rebuild than the economics are to fix.

Understanding how these instruments interact with your broader financing structure is essential. The guide to common mistakes that kill an institutional raise covers the disclosure and data room failures that most often derail deals at this stage.

What Must Be Resolved Before Approaching a Series B Lead

There are four things to complete before you send the first outreach to a Series B lead. None of them require converting every instrument. All of them require doing the work before the data room opens.

Step 1: Disclose every non-standard instrument in the data room.

This means the governing plan document, every grant notice or award agreement, any amendments, and a participant schedule showing who holds what and on what terms. Do not summarize. Provide the source documents. Investors' counsel will read them.

Step 2: Model the contingent cash obligation at multiple exit values.

Build a simple schedule showing the total payout obligation under each plan at $75M, $150M, $250M, and $400M exits. This gives investors what they need to underwrite the economics without doing the work themselves. It also signals that management understands its own obligations.

Step 3: Confirm subordination to preferred stockholder rights.

Work with counsel to confirm that no phantom plan or SAR agreement contains consent rights, veto rights, or payout triggers that conflict with the preferred stock protections in the financing. If conflicts exist, amend the plan documents before going to market. This is not optional.

Step 4: Prepare a phantom equity summary memo.

A one-to-two-page memo explaining each instrument, the total participant count, the aggregate obligation at a representative exit value, the subordination status, and why management believes the cap table is diligence-ready. This memo goes in the data room alongside the source documents.

Getting your valuation framework right before this work begins matters too. The complete startup valuation guide for founders walks through how institutional investors model company value and what adjustments they make for contingent obligations.

When Conversion Is the Right Answer, and When Disclosure Is Enough

Investors prefer standard equity. But what they actually require is visibility and control over the obligation set. Conversion is one way to achieve that. Proper disclosure and subordination is another.

Convert to standard equity when:

• The plan covers a small number of current employees
• The company has enough runway to complete a 409A and issue replacement option grants before the raise
• The phantom plan or SAR program has no participant consent requirement that would make conversion operationally difficult
• Conversion eliminates more risk than it creates in administrative delay

Disclosure and subordination may be sufficient when:

• The participant group is large or geographically dispersed, making conversion impractical on a pre-raise timeline
• The tax consequences of conversion for participants are material enough to create friction or legal exposure
• The instruments are well-documented, the obligations are clearly modeled, and no plan terms conflict with preferred stockholder protections

The deciding question is not which approach is cleaner in the abstract. It is which approach lets a lead investor model the economics, confirm that no hidden rights sit ahead of or alongside preferred protections, and move forward with confidence.

Key point: Converting a phantom plan creates a Section 409A compliance event and may require a new 409A valuation. Modifying or replacing cash-settled SARs triggers remeasurement under ASC 718. Both steps require counsel. Do not attempt either without legal advice.

Pre-Series B Cleanup Checklist

Complete each item before your first outreach to a Series B lead.

• Inventory every phantom equity plan, SAR program, profits interest, and synthetic equity arrangement
• Confirm the governing document, all grant notices, and all amendments are in your possession
• Build a contingent obligation schedule at $75M, $150M, $250M, and $400M exits
• Review plan terms for consent rights, veto rights, information rights, and payout triggers that may conflict with preferred stock protections
• Amend any conflicting terms before going to market
• Assess whether conversion to standard equity is feasible and appropriate given timeline and participant count
• Prepare a phantom equity summary memo for the data room
• Load all source documents, the obligation schedule, and the summary memo into the data room before first investor meetings

For a complete playbook on raising institutional capital at the Series B level, the guide on how to raise $100M the right way covers the full preparation sequence from data room to close.

Frequently Asked Questions

Does phantom equity count toward fully diluted share count in a Series B analysis?

Phantom equity does not represent issued shares, so it does not appear in a standard fully diluted share count. However, institutional investors performing Series B diligence treat phantom equity obligations as economic equivalents to equity when modeling exit proceeds. If your phantom plan covers 5% of equity value, an investor will reduce the proceeds available to the cap table by that amount, regardless of how the shares are counted.

How do cash-settled SARs affect enterprise value in a Series B?

Cash-settled SARs are classified as liabilities under FASB ASC 718 and remeasured at fair value each period. In enterprise value calculations, investors add this liability to the equity value, which reduces the implied equity value available to stockholders. A $3M SAR liability at a $60M enterprise value means the equity value to cap table holders is $57M, not $60M.

What does subordination mean in the context of a phantom equity plan?

Subordination means the phantom plan's payment rights are contractually junior to preferred stockholder liquidation preferences and the company's obligations under the financing documents. A properly subordinated plan cannot be triggered in a way that diverts proceeds away from preferred holders before their liquidation preference is satisfied.

Do phantom equity holders have any rights in a Series B financing?

Phantom equity holders are not stockholders. They have no voting rights, no anti-dilution rights, and no statutory right to participate in the financing. However, if their plan documents contain contractual consent rights, information rights, or payout triggers tied to financing events, those contractual rights are enforceable under Delaware law regardless of stockholder status.

How should a phantom equity plan be disclosed in the data room?

Include the full plan document, every grant notice and award agreement, any amendments or side letters, a participant schedule with grant dates and vesting status, and a contingent obligation schedule showing the total payout at several exit values. A one-page summary memo explaining each instrument and its subordination status should accompany the source documents.

Does phantom equity need to be converted before a Series B can close?

No. Conversion is one option, not a requirement. A Series B can close with phantom equity in place if the plan is fully disclosed, the obligations are modeled and understood by investors, the plan terms do not conflict with the preferred stock protections, and investors are comfortable with the residual obligation. Conversion is cleaner when feasible, but disclosure and subordination are often sufficient.

Can profits interests create UBTI issues for tax-exempt LPs in a Series B?

Profits interests held in an LLC structure can generate unrelated business taxable income (UBTI) for tax-exempt investors such as pension funds and endowments if the LLC is treated as a partnership for tax purposes and the income is from an active business. This is a structuring issue that requires tax counsel review before a Series B that includes tax-exempt LP capital. Founders should flag any LLC-level profits interests to counsel early in the raise preparation process.

Continue reading this series:

• How to Raise Capital in 2026 for Your Series A Round
• How to Raise Capital for a Startup: Complete Guide to Funding in 2026
• The Easiest Way to Raise Capital for Your Business

The wrong structure doesn't just cost you this round. It costs you the next three. IRC Partners advises founders raising $5M to $250M of institutional capital. If you're about to go to market and want the structure reviewed before investors see it, book a call here